Ainos, Inc. Files S-1 Amendment for Public Offering
Ticker: AIMDW · Form: S-1 · Filed: Apr 8, 2024 · CIK: 1014763
| Field | Detail |
|---|---|
| Company | Ainos, INC. (AIMDW) |
| Form Type | S-1 |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $3,782,830, $2.16, $8.25, $2.3 million, $1.16 |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1 Filing, Ainos Inc, Securities Offering, IPO, SEC Filing
TL;DR
<b>Ainos, Inc. has filed an S-1 Amendment, indicating preparations for a public securities offering.</b>
AI Summary
Ainos, Inc. (AIMDW) filed a IPO Registration (S-1) with the SEC on April 8, 2024. Ainos, Inc. filed an S-1 Amendment on April 8, 2024. The company is incorporated in Texas and its fiscal year ends on December 31. Its principal executive offices are located at 8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108. The filing is for a registration statement under the Securities Act of 1933. Ainos, Inc. is classified as a smaller reporting company and a non-accelerated filer.
Why It Matters
For investors and stakeholders tracking Ainos, Inc., this filing contains several important signals. This S-1 filing signals Ainos, Inc.'s intent to raise capital through the sale of securities to the public. As a smaller reporting company, this filing is a crucial step for Ainos, Inc. to access public markets and potentially fund future growth or operations.
Risk Assessment
Risk Level: low — Ainos, Inc. shows low risk based on this filing. The filing is an S-1 amendment, which is a standard procedural document for companies preparing for an IPO or public offering, and does not contain specific financial performance data or operational details that would indicate immediate risk.
Analyst Insight
Monitor future filings for details on the offering size, pricing, and use of proceeds to assess the potential impact on the company's capital structure and valuation.
Key Numbers
- 2024-04-08 — Filing Date (Date the S-1 Amendment was filed)
- 333-278556 — SEC File Number (Registration number for the filing)
- 1996-05-16 — Date of Name Change (Former company name was Amarillo Biosciences Inc.)
Key Players & Entities
- Ainos, Inc. (company) — Filer name and registrant name
- 20240408 (date) — Filing date
- S-1 (document) — Form type
- Texas (jurisdiction) — State of incorporation
- 2834 (industry_code) — Standard Industrial Classification Code
- 751974352 (id_number) — IRS Employer Identification Number
- San Diego, CA (location) — Principal executive offices location
- CT Corporation System (company) — Agent for service
FAQ
When did Ainos, Inc. file this S-1?
Ainos, Inc. filed this IPO Registration (S-1) with the SEC on April 8, 2024.
What is a S-1 filing?
A S-1 is a registration statement for initial public offerings, containing the prospectus with business description, financials, and risk factors. This particular S-1 was filed by Ainos, Inc. (AIMDW).
Where can I read the original S-1 filing from Ainos, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Ainos, Inc..
What are the key takeaways from Ainos, Inc.'s S-1?
Ainos, Inc. filed this S-1 on April 8, 2024. Key takeaways: Ainos, Inc. filed an S-1 Amendment on April 8, 2024.. The company is incorporated in Texas and its fiscal year ends on December 31.. Its principal executive offices are located at 8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108..
Is Ainos, Inc. a risky investment based on this filing?
Based on this S-1, Ainos, Inc. presents a relatively low-risk profile. The filing is an S-1 amendment, which is a standard procedural document for companies preparing for an IPO or public offering, and does not contain specific financial performance data or operational details that would indicate immediate risk.
What should investors do after reading Ainos, Inc.'s S-1?
Monitor future filings for details on the offering size, pricing, and use of proceeds to assess the potential impact on the company's capital structure and valuation. The overall sentiment from this filing is neutral.
How does Ainos, Inc. compare to its industry peers?
Ainos, Inc. operates within the Pharmaceutical Preparations industry (SIC 2834).
Are there regulatory concerns for Ainos, Inc.?
The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.
Industry Context
Ainos, Inc. operates within the Pharmaceutical Preparations industry (SIC 2834).
Regulatory Implications
The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.
What Investors Should Do
- Review the full S-1 registration statement for detailed financial information and business operations.
- Track subsequent amendments and filings for updates on the public offering details.
- Analyze the company's business strategy and market position once more information becomes available.
Year-Over-Year Comparison
This is an S-1 Amendment filing, indicating a new registration process rather than a comparison to a prior period's filing.
Filing Stats: 4,474 words · 18 min read · ~15 pages · Grade level 15.6 · Accepted 2024-04-08 16:06:07
Key Financial Figures
- $3,782,830 — missory note in the principal amount of $3,782,830 issued to Lind (the “Note”)
- $2.16 — n this prospectus, we may receive up to $2.16 per share upon the cash exercise of the
- $8.25 — exercise of the Lind Warrant and up to $8.25 per share upon the cash exercise of the
- $2.3 million — gregate gross proceeds of approximately $2.3 million. However, we cannot predict when and in
- $1.16 — ing sale price for our common stock was $1.16. Investing in our securities involves
- $5 million — . The Company will pay a total fee of NT$5 million (approximately USD$161,000) for five-ye
- $161,000 — l fee of NT$5 million (approximately USD$161,000) for five-years of development commenci
- $95,000 — OCT technologies for a monthly fee of US$95,000 (plus 5% sales tax), with negotiable pa
- $250 million — reporting company” until we have $250 million or more in public float (based on our c
- $700 m — on our common stock) that is less than $700 million, annual revenues of $100 million
- $100 million — s than $700 million, annual revenues of $100 million or more during the most recently comple
- $10 million — an aggregate principal amount of up to $10 million under various tranches (the “Fina
- $2.0 million — , the initial closing date, Lind funded $2.0 million (less commitment fees) to the Company o
- $3.0 million — mitment fees) to the Company out of the $3.0 million “First Funding Amount” (as
- $1.0 million — e Agreement). Lind funded the remaining $1.0 million (less commitment fees) on December 21,
Filing Documents
- forms-1.htm (S-1) — 352KB
- ex5-1.htm (EX-5.1) — 33KB
- ex23-1.htm (EX-23.1) — 7KB
- ex107.htm (EX-FILING FEES) — 22KB
- forms-1_001.jpg (GRAPHIC) — 5KB
- ex5-1_001.jpg (GRAPHIC) — 7KB
- ex5-1_002.jpg (GRAPHIC) — 3KB
- ex23-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-013774.txt ( ) — 443KB
USE OF PROCEEDS
USE OF PROCEEDS 7 DETERMINATION OF OFFERING PRICE 7 SELLING STOCKHOLDERS 8 PLAN OF DISTRIBUTION 9
DESCRIPTION OF CAPITAL STOCK AND SECURITIES BEING OFFERED
DESCRIPTION OF CAPITAL STOCK AND SECURITIES BEING OFFERED 11 LEGAL MATTERS 13 EXPERTS 13 WHERE YOU CAN FIND MORE INFORMATION 13 i CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements in this prospectus are “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business strategy and our financing plans. The forward-looking statements in this prospectus are not based on historical facts, but rather reflect the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified by the use of terms such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “foresee,” “may,” “guidance,” “estimate,” “potential,” “outlook,” “target,” “forecast,” “likely” or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. Forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations for various reasons. You should review carefully all information in this prospectus and the documents that we reference herein and have filed as exhibits to the Annual